CagriSema cut 'food noise' and fat around the organs in new Novo data shown at EASD
Novo says a 52-week brain-scan study found its investigational semaglutide-plus-cagrilintide jab reduced cravings, hunger and 'food noise' alongside 22.4% placebo-adjusted weight loss. Separate type 2 diabetes studies showed less fat around the liver and pancreas and early signs that bone health held up. CagriSema is still investigational.
Image credit: Novo Nordisk (press release via NTB, Norwegian)
Source: Novo Nordisk (press release via NTB, Norwegian) (19 Oct 2026).